Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Dec 18;99(51):e23637.
doi: 10.1097/MD.0000000000023637.

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis

Mohamed A Yassin  1 , Mohamed O Abdel Rahman  2 , Anas A Hamad  3 , Abdul Razzakh Poil  4 , Mohamed T Abdelrazek  5 , Radwa M Hussein  3 , Nancy A Kassem  3 , Afraa M Fadul  1 , Sarah A Elkourashy  1 , Abdulqadir J Nashwan  1
Affiliations
Comparative Study

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis

Mohamed A Yassin et al. Medicine (Baltimore). .

Abstract

The main aim of this study is to compare the 2 medications denosumab and zoledronic acid for patients with beta-thalassemia major induced osteoporosis. Patients with B-thalassemia major induced osteoporosis will undergo baseline assessment of the bone densitometry by bone density(DEXA) scan as a standard of care by the radiology department, then a blood test for bone-specific alkaline phosphatase and type-1 collagen telopeptide will be measured by the chemistry laboratory.Patients with B-thalassemia major induced osteoporosis, who are 18 years of age or more and willing to participate in the study will be enrolled after consenting by the primary investigator in hematology outpatient clinics. Patients with osteoporosis will receive 1 of the 2 medications; at the end of the year, DEXA scan will be done to compare the response of the 2 medications. The potential risks include drug-related side effects.The outcome will be measured biochemically by measuring bone-specific alkaline phosphatase and type 1 collagen carboxy telopeptide and radiologically by DEXA scan at baseline and 1 year using Z score.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. De Sanctis V, Soliman AT, Elsedfy H, et al. Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 2013;11:167. - PubMed
    1. Baldini M, Forti S, Marcon A, et al. Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 2010;89:1207–13. - PubMed
    1. Kyriakou A, Savva SC, Savvides I, et al. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev 2008;6:116–22. - PubMed
    1. Mahachoklertwattana P, Pootrakul P, Chuansumrit A, et al. Association between bone mineral density and erythropoiesis in Thai children and adolescents with thalassemia syndromes. J Bone Miner Metab 2006;24:146–52. - PubMed
    1. Pietrapertosa A, Minenna G, Colella S, et al. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. Panminerva Med 2009;51:17–23. - PubMed

Publication types

MeSH terms